Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of

Indication
Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form; Septo-Optic Dysplasia

Other upcoming events for RYTM

Phase 2 ReadoutPhase 2 Readout: setmelanotide
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of S
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of
Patent ExpiryPatent/Exclusivity Expiry: IMCIVREE

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of — RYTM Phase 3 Readout | BioSniper